Pharmaceutical stocks once again set off a wave of ups and downs, and also obtained the main funds to continue to increase holdings

【Pharmaceutical Network Pharmaceutical Stock Market】On December 7, the pharmaceutical industry as a whole was active, and pharmaceutical stocks led by anti-virus once again set off a tide
of ups and downs.
Among them, Yiling Pharmaceutical is close to the price limit, and the stock price has reached a record high, with a total market value of more than 80 billion
.
Nearly 20 shares of Gonggong Pharmaceutical, Sinotherapeutical, Haichen Pharmaceutical, Qianhong Pharmaceutical, Xinhua Pharmaceutical, Guizhou Bailing, etc.
; In addition, Shanghai Kaibao, Hendi Pharmaceutical, Guangshengtang, Fu'an Pharmaceutical, etc.
rose by more than 10%.

Among them, Yiling Pharmaceutical is undoubtedly the focus
of attention in the industry.
Since its launch on September 27, the stock has risen by more than 160%.

It is understood that in less than two months since the end of September, the stock price of Yiling Pharmaceutical has risen
all the way from about 18.
8 yuan.
Especially since entering November, with the amplification of trading volume, Yiling Pharmaceutical issued two change announcements due to the continuous surge in stock prices, and hit a record high
of 48.
66 yuan per share on November 21.
Although on December 6, the stock soared back down and finally closed at 44.
65 yuan, down 2.
08%, but the transaction volume exceeded 10 billion yuan
throughout the day.
For the rise in the stock price of Yiling Pharmaceutical, the industry generally believes that it is caused
by the hot sales of Lianhua Qingwen products.
It is worth mentioning that on the evening of December 6, Yiling Pharmaceutical also said on the investor interactive platform that the company's supply price of Lianhua Qingwen has remained stable
recently.
If consumers find that individual terminals have price increases, please report
to the relevant local departments in time.
At present, the company is taking various measures to expand production and make every effort to ensure market supply
.
Today, in addition to the outbreak of pharmaceutical stocks, many stocks rose to the limit; In fact, pharmaceutical stocks have also received the main funds to continue to increase their holdings, with a net purchase of more than 2 billion yuan
.
In terms of individual stocks, Xinhua Pharmaceutical bought a net of 280 million yuan, Renhe Pharmaceutical and Yiling Pharmaceutical all bought more than 200 million yuan, and Zhendong Pharmaceutical, Qianhong Pharmaceutical, Changjiang Health, Baiyunshan, Hongri Pharmaceutical, Yuheng Pharmaceutical, and Guizhou Sanli all received net purchases
from main funds.
Xinhua Pharmaceutical is an important manufacturer of antipyretic and analgesic APIs in the world, including ibuprofen, aspirin, metamizole and other varieties, and the actual market share of ibuprofen is close to 40%.

It is understood that in recent times, Xinhua Pharmaceutical has been frequently increasing its holdings, such as yesterday's southbound capital once again increased its holdings of Xinhua Pharmaceutical's H shares by 12,000 shares, which is an increase for three consecutive days
.
On December 5, Xinhua Pharmaceutical received 1,328,900 shares from Shenzhen Stock Connect, and the latest holding volume was 4,787,600 shares, accounting for 1.
01%
of the company's total A-share capital.
Net purchases on the day also reached $124 million
.
This morning, while Xinhua Pharmaceutical received a large increase in holdings, it was also sharply pulled up by H shares by more than 10% to HK$6.
67, and A-shares rose more than 8% to 26.
55 yuan
.
Industry analysts believe that from today's pharmaceutical sector ushered in a strong repair, it can be seen that the concept of prevention and treatment still maintains a high degree of activity, but it should be noted that the sharp fluctuation of high-end amplification is a signal of loose chips, so more attention needs to be paid to risk control
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.